Advertisement
MRNA vs PCVX
Which Stock Would AI Choose? Moderna (MRNA) vs. Vaxcyte (PCVX) Stock Comparison
Key Takeaways
- Both MRNA and PCVX operate in the vaccine development space within the biotechnology sector, with MRNA leveraging mRNA technology across respiratory and other indications while PCVX focuses on conjugate and protein-based vaccines for bacterial diseases.
- Recent market activity shows PCVX delivering stronger year-to-date returns compared to MRNA, supported by completion of key Phase 3 trial enrollments.
- MRNA has secured international supply contracts, such as for its respiratory syncytial virus (RSV) vaccine, amid ongoing cost management and pipeline diversification efforts.
- Risk profiles differ, with MRNA navigating U.S. regulatory and market sentiment challenges, while PCVX advances its late-stage pneumococcal candidates with substantial cash reserves.
- Sector exposure remains similar in healthcare innovation, though relative momentum and clinical progress create distinct trade-offs for investors monitoring vaccine stocks.
- Market sentiment reflects broader biotech volatility, with both companies positioned for potential catalysts from ongoing trials and regulatory reviews.
Introduction
Investors and traders frequently compare biotechnology stocks like MRNA and PCVX to assess relative positioning within the vaccine and infectious disease treatment landscape. These companies represent different technological approaches to vaccine development, making the comparison relevant for those evaluating growth drivers, clinical pipelines, and market dynamics in a sector influenced by regulatory developments and public health needs. This analysis focuses on observable factors such as recent performance, business models, and sentiment to provide a balanced view suitable for experienced market participants and those new to biotech equities.
Moderna (MRNA) Overview and Recent Performance
Moderna, Inc. develops medicines based on messenger ribonucleic acid (mRNA) technology, with a portfolio spanning respiratory vaccines for conditions such as COVID-19, RSV, and influenza, alongside candidates in oncology and rare diseases. In recent weeks, the stock has experienced fluctuations amid broader healthcare sector movements and company-specific updates. Key influences include an EU contract for RSV vaccine supply and progress on flu vaccine candidates, alongside cost-cutting measures and a shift toward international markets. Sentiment has been shaped by ongoing pipeline diversification efforts and quarterly financial reporting expectations, with the company scheduled to release second-quarter 2026 results later in the month. Relative performance reflects typical biotech volatility tied to clinical and regulatory milestones.
Vaxcyte (PCVX) Overview and Recent Performance
Vaxcyte, Inc. is a clinical-stage company developing conjugate and novel protein vaccines targeting bacterial infectious diseases, including its lead pneumococcal conjugate vaccine candidates. Recent market activity has highlighted completion of Phase 3 trial enrollments for its 31-valent candidate and initiation of early-stage studies for additional programs. The stock has shown resilience with positive year-to-date gains, supported by a strong cash position and participation in investor conferences during July 2026. Sentiment benefits from clinical advancement in a focused pipeline, contributing to relative outperformance against broader market benchmarks in recent periods. Performance reflects steady progress in late-stage development without the same level of commercial revenue generation as more established peers.
Trending AI Robots
Tickeron’s Trending AI Robots page curates a selection of high-performing AI trading bots from hundreds available on the platform. These bots trade thousands of different tickers using varied strategies, timeframes, and performance metrics tailored to current market conditions. Only the most suitable and effective ones earn placement in the trending section, where users can review statistics such as win rates, profit factors, and drawdown ranges across diverse trading styles. This resource allows traders to explore automated approaches suited to equities like vaccine stocks. For more details, visit Trending AI Robots.
Head-to-Head Comparison
Moderna employs an mRNA platform enabling rapid vaccine design across multiple therapeutic areas, while Vaxcyte specializes in conjugate vaccines optimized for bacterial pathogens using cell-free protein synthesis. Growth drivers for MRNA include expanding respiratory offerings and oncology assets, contrasted with PCVX’s emphasis on broad-spectrum pneumococcal protection and early-stage bacterial targets. Recent momentum favors PCVX on clinical enrollment milestones and sustained returns, whereas MRNA benefits from established partnerships and supply agreements. Risk factors for MRNA involve U.S. market access uncertainties, while PCVX faces typical clinical-stage development timelines despite its cash buffer. Both maintain healthcare sector exposure, though differing maturity levels create trade-offs in stability versus growth potential. Market sentiment remains tied to verifiable trial outcomes and regulatory pathways rather than broader speculation.
Tickeron AI Verdict
Based on observable factors such as recent clinical progress, relative price stability, and momentum indicators, Tickeron’s AI would currently assign a probabilistic edge to PCVX due to consistent trial advancements and stronger year-to-date positioning. MRNA demonstrates resilience through international catalysts and pipeline breadth, suggesting potential for balanced consideration depending on timeframe and risk tolerance. This assessment draws from trend consistency and sector positioning without implying definitive outcomes.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MRNA is a Hold and PCVX is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
MRNA’s FA Score shows that 1 FA rating(s) are green whilePCVX’s FA Score has 0 green FA rating(s).
- MRNA’s FA Score: 1 green, 4 red.
- PCVX’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
MRNA’s TA Score shows that 4 TA indicator(s) are bullish while PCVX’s TA Score has 3 bullish TA indicator(s).
- MRNA’s TA Score: 4 bullish, 6 bearish.
- PCVX’s TA Score: 3 bullish, 5 bearish.
Price Growth
MRNA (@Biotechnology) experienced а -7.01% price change this week, while PCVX (@Biotechnology) price change was +5.24% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +6.94%. For the same industry, the average monthly price growth was +0.31%, and the average quarterly price growth was +2915.40%.
Reported Earning Dates
MRNA is expected to report earnings on Oct 29, 2026.
PCVX is expected to report earnings on Aug 12, 2026.
Industries' Descriptions
@Biotechnology (+6.94% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| MRNA | PCVX | MRNA / PCVX | |
| Capitalization | 23.6B | 8.64B | 273% |
| EBITDA | -2.8B | -1.06B | 264% |
| Gain YTD | 82.638 | 27.633 | 299% |
| P/E Ratio | N/A | N/A | - |
| Revenue | 2.21B | 0 | - |
| Total Cash | 5.14B | 1.74B | 296% |
| Total Debt | 1.29B | 116M | 1,109% |
MRNA | PCVX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 56 | 59 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 79 Overvalued | 69 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 77 | |
SMR RATING 1..100 | 99 | 98 | |
PRICE GROWTH RATING 1..100 | 50 | 44 | |
P/E GROWTH RATING 1..100 | 3 | 49 | |
SEASONALITY SCORE 1..100 | 50 | 90 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
PCVX's Valuation (69) in the null industry is in the same range as MRNA (79) in the Biotechnology industry. This means that PCVX’s stock grew similarly to MRNA’s over the last 12 months.
PCVX's Profit vs Risk Rating (77) in the null industry is in the same range as MRNA (100) in the Biotechnology industry. This means that PCVX’s stock grew similarly to MRNA’s over the last 12 months.
PCVX's SMR Rating (98) in the null industry is in the same range as MRNA (99) in the Biotechnology industry. This means that PCVX’s stock grew similarly to MRNA’s over the last 12 months.
PCVX's Price Growth Rating (44) in the null industry is in the same range as MRNA (50) in the Biotechnology industry. This means that PCVX’s stock grew similarly to MRNA’s over the last 12 months.
MRNA's P/E Growth Rating (3) in the Biotechnology industry is somewhat better than the same rating for PCVX (49) in the null industry. This means that MRNA’s stock grew somewhat faster than PCVX’s over the last 12 months.
| MRNA | PCVX | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 73% | 2 days ago 75% |
| Stochastic ODDS (%) | 2 days ago 74% | 2 days ago 74% |
| Momentum ODDS (%) | 2 days ago 76% | 2 days ago 74% |
| MACD ODDS (%) | 2 days ago 90% | 2 days ago 80% |
| TrendWeek ODDS (%) | 2 days ago 78% | 2 days ago 76% |
| TrendMonth ODDS (%) | 2 days ago 87% | 2 days ago 75% |
| Advances ODDS (%) | 5 days ago 79% | 4 days ago 78% |
| Declines ODDS (%) | 3 days ago 87% | 6 days ago 71% |
| BollingerBands ODDS (%) | 5 days ago 90% | 2 days ago 74% |
| Aroon ODDS (%) | 2 days ago 84% | 2 days ago 78% |
Advertisement
PCVX and
Correlation & Price change
A.I.dvisor indicates that over the last year, PCVX has been loosely correlated with VIR. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if PCVX jumps, then VIR could also see price increases.
| Ticker / NAME | Correlation To PCVX | 1D Price Change % | ||
|---|---|---|---|---|
| PCVX | 100% | +5.31% | ||
| VIR - PCVX | 52% Loosely correlated | -3.79% | ||
| SRRK - PCVX | 47% Loosely correlated | +9.96% | ||
| DNLI - PCVX | 47% Loosely correlated | +1.27% | ||
| BCAX - PCVX | 47% Loosely correlated | +6.26% | ||
| KURA - PCVX | 46% Loosely correlated | +0.87% | ||
More | ||||